Implication of VEGFR2 Polymorphism on the Prognosis of Anlotinib Monotherapy for Patients With Treatment-Refractory Advanced NSCLC: An Exploratory Study

Background: This study aimed to investigate the implication of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) polymorphism on the prognosis of anlotinib monotherapy among patients with treatment-refractory advanced nonsmall cell lung cancer (NSCLC). Methods: Designed as a retrospective study...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiaoyuan, Cheng, Yang, Zhu, Baorang, Geng, Ming, Yan, Peng, Hu, Mu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047798/
https://www.ncbi.nlm.nih.gov/pubmed/35443836
http://dx.doi.org/10.1177/15330338221080993

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047798/
https://www.ncbi.nlm.nih.gov/pubmed/35443836
http://dx.doi.org/10.1177/15330338221080993

Ejemplares similares